The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

Overview

About this study

The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age, ≥ 18 years old.
  • Must speak English as primary language.
  • Must have an informant who can provide an independent evaluation of functioning.
  • Bilingual patients and ethnic and racial minorities whose primary language is English will be eligible.
  • Each new patient must present with a chief complaint of progressive impairment of speech or language and must have evidence of AOS documented by a speech-language pathologist during routine clinical evaluation.
  • At study entry, all patients must have speech sufficiently intelligible for a confident diagnosis of AOS, dysarthria, and/or aphasia, and for acoustic analysis.
  • Patients with aphasia will be included, as long as AOS is also present, regardless of whether the aphasia or AOS is more dominant (i.e., patients with aphasia, but without AOS, will not be eligible).
  • Patients with dysarthria will be included as long as the aphasia and/or apraxia of speech is more prominent.

Exclusion Criteria:

  • Any patient whose speech is not intelligible enough for confident speech-language diagnosis.
  • All patients with concurrent illnesses that could account for speech deficits (e.g., traumatic brain injury, strokes, developmental syndromes), and patients meeting criteria for another neurodegenerative disease (e.g., Alzheimer’s type dementia).
  • Patients with aphasia, but without apraxia of speech will be excluded.
  • Patients with dysarthria who do not have PAOS, or whose dysarthria at study entry is more severe than PAOS, will be excluded.
  • All women who are pregnant, or post-partum and breast-feeding, will be excluded as they are unable to undergo the required imaging.
  • All women who can become pregnant must have a pregnancy test no more than 48 hours before the DaTscan.
  • Patients will also be excluded if MRI is contraindicated (e.g., metal in head, cardiac pace maker), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g., structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g., chemotherapy).
  • Patients will be excluded if they do not have an informant, or do not consent to the research.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Keith Josephs, M.D.

Open for enrollment

Contact information:

Sarah Boland CCRP

(507)284-3863

Boland.Sarah@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20342653

Mayo Clinic Footer